Insight into the binding mode for cyclopentapeptide antagonists of the CXCR4 receptor

Chemical Biology and Drug Design

Volumn 67, Issue 5, 2006, Pages 346-354

  Våbenø, Jon ^a   Nikiforovich, Gregory V ^a   Marshall, Garland R ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Binding mode; CXCL12; CXCR4 antagonists; Cyclopentapeptides; Docking; Homology modeling; Human immunodeficiency virus; Metastasis; Receptor bound conformation; Stromal cell derived factor 1

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CYCLOPEPTIDE; G PROTEIN COUPLED RECEPTOR; GLYCOPROTEIN GP 120; LIGAND; PENTAPEPTIDE; VIRUS GLYCOPROTEIN;

ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; CONFORMATION; DRUG RECEPTOR BINDING; HUMAN IMMUNODEFICIENCY VIRUS; LIGAND BINDING; MUTATION; PRIORITY JOURNAL; RECEPTOR BINDING;

AMINO ACID SEQUENCE; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR SEQUENCE DATA; PEPTIDES, CYCLIC; POINT MUTATION; PROTEIN STRUCTURE, SECONDARY; RECEPTORS, CXCR4; RHODOPSIN; SEQUENCE ALIGNMENT;

EID: 33745216928     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2006.00387.x     Document Type: Article

References (48)

1. Bleul C.C. Farzan M. Choe H. Parolin C. Clark-Lewis I. Sodroski J. Springer T.A. ( 1996) The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 382 : 829 833.
2. Oberlin E. Amara A. Bachelerie F. Bessia C. Virelizier J.-L. Arenzana-Seisdedos F. Schwartz O. et al. ( 1996) The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 382 : 833 835.
3. Feng Y. Broder C.C. Kennedy P.E. Berger E.A. ( 1996) HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272 : 872 877.
4. Berson J.F. Long D. Doranz B.J. Rucker J. Jirik F.R. Doms R.W. ( 1996) A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. J Virol 70 : 6288 6295.
5. Tersmette M. de Goede R.E. Al B.J. Winkel I.N. Gruters R.A. Cuypers H.T. Huisman H.G. et al. ( 1988) Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J Virol 62 : 2026 2032.
6. Tersmette M. Lange J.M. de Goede R.E. de Wolf F. Eeftink-Schattenkerk J.K. Schellekens P.T. Coutinho R.A. et al. ( 1989) Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet 1 : 983 985.
7. Tersmette M. Gruters R.A. de Wolf F. de Goede R.E. Lange J.M. Schellekens P.T. Goudsmit J. et al. ( 1989) Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol 63 : 2118 2125.
8. Richman D.D. Bozzette S.A. ( 1994) The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 169 : 968 974.
9. Connor R.I. Ho D.D. ( 1994) Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. J Virol 68 : 4400 4408.
10. Connor R.I. Sheridan K.E. Ceradini D. Choe S. Landau N.R. ( 1997) Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 185 : 621 628.
11. Zhang L. He T. Huang Y. Chen Z. Guo Y. Wu S. Kunstman K.J. et al. ( 1998) Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1. J Virol 72 : 9307 9312.
12. De Clercq E. ( 2003) The bicyclam AMD3100 story. Nat Rev Drug Discov 2 : 581 587.
13. Ichiyama K. Yokoyama-Kumakura S. Tanaka Y. Tanaka R. Hirose K. Bannai K. Edamatsu T. et al. ( 2003) A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A 100 : 4185 4190.
14. Murakami T. Yoshida A. Tanaka R. Mitsuhashi S. Hirose K. Yanaka M. Yamamoto N. et al. ( 2004) KRH-2731: an orally bioavailable CXCR4 antagonist is a potent inhibitor of HIV-1 infection. In : 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004, San Francisco, CA, USA, Abstract No. 541.
15. Doranz B.J. Grovit-Ferbas K. Sharron M.P. Mao S.-H. Goetz M.B. Daar E.S. Doms R.W. et al. ( 1997) A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med 186 : 1395 1400.
16. Fujii N. Nakashima H. Tamamura H. ( 2003) The therapeutic potential of CXCR4 antagonists in the treatment of HIV. Exp Opin Invest Drugs 12 : 185 195.
17. Tamamura H. Araki T. Ueda S. Wang Z. Oishi S. Esaka A. Trent J.O. et al. ( 2005) Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds. J Med Chem 48 : 3280 3289.
18. Fujii N. Oishi S. Hiramatsu K. Araki T. Ueda S. Tamamura H. Otaka A. et al. ( 2003) Molecular-size reduction of a potent CXCR4-chemokine antagonist using orthogonal combination of conformation- and sequence-based libraries. Angew Chem Int Ed Engl 42 : 3251 3253.
19. Tamamura H. Mizumoto M. Hiramatsu K. Kusano S. Terakubo S. Yamamoto N. Trent J.O. et al. ( 2004) Topochemical exploration of potent compounds using retro-enantiomer libraries of cyclic pentapeptides. Org Biomol Chem 2 : 1255 1257.
20. Våbenø J. Nikiforovich G.V. Marshall G.R. ( 2006) A minimalistic 3D pharmacophore model for cyclopentapeptide CXCR4 antagonists. Biopolymers, in press doi 10.1002/bip. 20508.
21. Palczewski K. Kumasaka T. Hori T. Behnke C.A. Motoshima H. Fox B.A. Le Trong I. et al. ( 2000) Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289 : 739 745.
22. Nikiforovich G.V. Marshall G.R. ( 2001) 3D model for TM region of the AT-1 receptor in complex with angiotensin II independently validated by site-directed mutagenesis data. Biochem Biophys Res Commun 286 : 1204 1211.
23. 1 receptor. J Pept Res 66 : 236 248.
24. Ballesteros J.A. Weinstein H. ( 1995) Integrated methods for the construction of three dimensional models and computational probing of structure-function relations in G-protein coupled receptors. Methods Neurosci 25 : 366 428.
25. Dunfield L.G. Burgess A.W. Scheraga H.A. ( 1978) Energy parameters in polypeptides. 8. Empirical potential energy algorithm for the conformational analysis of large molecules. J Phys Chem 82 : 2609 2616.
26. Nemethy G. Pottle M.S. Scheraga H.A. ( 1983) Energy parameters in polypeptides. 9. Updating of geometrical parameters, nonbonded interactions, and hydrogen bond interactions for the naturally occurring amino acids. J Phys Chem 87 : 1883 1887.
27. Nikiforovich G.V. Hruby V.J. Prakash O. Gehrig C.A. ( 1991) Topographical requirements for δ-selective opioid peptides. Biopolymers 31 : 941 955.
28. Morris G.M. Goodsell D.S. Halliday R.S. Huey R. Hart W.E. Belew R.K. Olson A.J. ( 1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19 : 1639 1662.
29. Mirzadegan T. Benko G. Filipek S. Palczewski K. ( 2003) Sequence analyses of G-protein-coupled receptors: similarities to rhodopsin. Biochemistry 42 : 2759 2767.
30. Tamamura H. Esaka A. Ogawa T. Araki T. Ueda S. Wang Z. Trent J.O. et al. ( 2005) Structure-activity relationship studies on CXCR4 antagonists having cyclic pentapeptide scaffolds. Org Biomol Chem 3 : 4392 4394.
31. Ling K. Wang P. Zhao J. Wu Y.-L. Cheng Z.-J. Wu G.-X. Hu W. et al. ( 1999) Five-transmembrane domains appear sufficient for a G protein-coupled receptor: functional five-transmembrane domain chemokine receptors. Proc Natl Acad Sci U S A 96 : 7922 7927.
32. Trent J.O. Wang Z.-x. Murray J.L. Shao W. Tamamura H. Fujii N. Peiper S.C. ( 2003) Lipid bilayer simulations of CXCR4 with inverse agonists and weak partial agonists. J Biol Chem 278 : 47136 47144.
33. Tamamura H. Xu Y. Hattori T. Zhang X. Arakaki R. Kanbara K. Omagari A. et al. ( 1998) A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun 253 : 877 882.
34. Tamamura H. Omagari A. Oishi S. Kanamoto T. Yamamoto N. Peiper S.C. Nakashima H. et al. ( 2000) Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes. Bioorg Med Chem Lett 10 : 2633 2637.
35. Gerlach L.O. Skerlj R.T. Bridger G.J. Schwartz T.W. ( 2001) Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J Biol Chem 276 : 14153 14160.
36. Tian S. Choi W.T. Liu D. Pesavento J. Wang Y. An J. Sodroski J.G. et al. ( 2005) Distinct functional sites for human immunodeficiency virus type 1 and stromal cell-derived factor 1α on CXCR4 transmembrane helical domains. J Virol 79 : 12667 12673.
37. Chabot D.J. Zhang P.-F. Quinnan G.V. Broder C.C. ( 1999) Mutagenesis of CXCR4 identifies important domains for human immunodeficiency virus type 1 X4 isolate envelope-mediated membrane fusion and virus entry and reveals cryptic coreceptor activity for R5 isolates. J Virol 73 : 6598 6609.
38. Brelot A. Heveker N. Montes M. Alizon M. ( 2000) Identification of residues of CXCR4 critical for human immunodeficiency virus coreceptor and chemokine receptor activities. J Biol Chem 275 : 23736 23744.
39. Rosenkilde M.M. Gerlach L.-O. Jakobsen J.S. Skerlj R.T. Bridger G.J. Schwartz T.W. ( 2004) Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor. J Biol Chem 279 : 3033 3041.
40. Wang Z.-x. Berson J.F. Zhang T.-y. Cen Y.-H. Sun Y. Sharron M. Lu Z.-h. et al. ( 1998) CXCR4 sequences involved in coreceptor determination of human immunodeficiency virus type-1 tropism. Unmasking of activity with M-tropic Env glycoproteins. J Biol Chem 273 : 15007 15015.
41. Zhou H. Tai H.-H. ( 2000) Expression and functional characterization of mutant human CXCR4 in insect cells: role of cysteinyl and negatively charged residues in ligand binding. Arch Biochem Biophys 373 : 211 217.
42. Hatse S. Princen K. Gerlach L.-O. Bridger G. Henson G. De Clercq E. Schwartz T.W. et al. ( 2001) Mutation of Asp171 and Asp262 of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100. Mol Pharmacol 60 : 164 173.
43. Hatse S. Princen K. Vermeire K. Gerlach L.-O. Rosenkilde M.M. Schwartz T.W. Bridger G. et al. ( 2003) Mutations at the CXCR4 interaction sites for AMD3100 influence anti-CXCR4 antibody binding and HIV-1 entry. FEBS Lett 546 : 300 306.
44. Zhou N. Luo Z. Luo J. Liu D. Hall J.W. Pomerantz R.J. Huang Z. ( 2001) Structural and functional characterization of human CXCR4 as a chemokine receptor and HIV-1 co-receptor by mutagenesis and molecular modeling studies. J Biol Chem 276 : 42826 42833.
45. Crump M.P. Gong J.-H. Loetscher P. Rajarathnam K. Amara A. Arenzana-Seisdedos F. Virelizier J.-L. et al. ( 1997) Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J 16 : 6996 7007.
46. Huang X. Shen J. Cui M. Shen L. Luo X. Ling K. Pei G. et al. ( 2003) Molecular dynamics simulations on SDF-1α: binding with CXCR4 receptor. Biophys J 84 : 171 184.
47. Tamamura H. Sugioka M. Odagaki Y. Omagari A. Kan Y. Oishi S. Nakashima H. et al. ( 2001) Conformational study of a highly specific CXCR4 inhibitor, T140, disclosing the close proximity of its intrinsic pharmacophores associated with strong anti-HIV activity. Bioorg Med Chem Lett 11 : 359 362.
48. 262 in the CXCR4 receptor. Biochemistry 42 : 710 717.